Argos Therapeutics (NASDAQ: ARGS) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Earnings and Valuation
This table compares Argos Therapeutics and Sinovac Biotech’s top-line revenue, earnings per share and valuation.
Sinovac Biotech has higher revenue and earnings than Argos Therapeutics. Sinovac Biotech is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and recommmendations for Argos Therapeutics and Sinovac Biotech, as provided by MarketBeat.com.
Argos Therapeutics presently has a consensus price target of $4.13, suggesting a potential upside of 2,367.66%. Given Argos Therapeutics’ higher possible upside, equities research analysts plainly believe Argos Therapeutics is more favorable than Sinovac Biotech.
Institutional & Insider Ownership
27.9% of Argos Therapeutics shares are held by institutional investors. Comparatively, 30.7% of Sinovac Biotech shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Argos Therapeutics and Sinovac Biotech’s net margins, return on equity and return on assets.
Sinovac Biotech beats Argos Therapeutics on 7 of the 10 factors compared between the two stocks.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.